Mursla Bio's AI platform expands across precision medicines arena
The company is acknowledged as a leader in Extracellular Vesicle (EV) science and is on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients.
It has announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling.
Mursla is engaging with potential partners to apply the platform to additional disease areas, biomarker discovery and IVD translation programmes. The platform is said to address a major gap in liquid biopsy and precision medicine – enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution.
Mursla’s platform is built on its ability to isolate and analyse EVs that are secreted by specific organs into the bloodstream. The platform is said to reduce non-target background by up to five orders of magnitude compared to standard bulk EV isolation so significantly improves data structure, enhancing prediction model generalisation.
The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH.
Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio’s method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development.
The platform incorporates optimised multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption.
The platform also underpins the development of EvoLiver™, the company’s lead clinical programme for liver cancer surveillance in cirrhotic patients.
Built on multi-omics data from over 300 patients, EvoLiver achieved 86 per cent sensitivity and 88 per cent specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection and has received Breakthrough Device Designation from America's FDA.
Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature’s native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample.
"It produces structured, biologically labelled datasets that are optimised for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.”